CEVEC licenses CAPGo technology in the field of veterinary vaccines
CEVEC licenses CAP(R)Go technology in the field of veterinary vaccines
Further step to establish CAP(R)Go as the production standard for difficult to express recombinant proteins First use of CAP(R)Go in the field of veterinary vaccines CEVEC grants license for the development, production and commercialization of veterinary vaccines based on CAP(R)Go technology
Cologne, Germany, July 06, 2017 - CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed a non-exclusive license agreement with a leading European veterinary pharmaceutical company for use of its proprietary CAP(R)Go cells in the development, production and commercialization of two difficult to express recombinant proteins in the field of veterinary vaccines.
Under the terms of the agreement, CEVEC provides its expertise in cell line development and in the expression of difficult-to-produce recombinant proteins utilizing its CAP(R)Go platform. Furthermore, the company has granted its contracting partner rights to use CEVEC's proprietary CAP(R)Go technology for the development, production and commercialization of certain protein products for the vaccination of livestock animals. The license agreement was the result of extensive previous studies delivering conclusive data on the effective and cost-efficient production of the proteins with the CAP(R)Go platform.
"We are very pleased to work with a leading company in animal health on this exciting project," commented Nico Scheer, Chief Business Officer of CEVEC. "The fact that CAP(R)Go cells were selected by our partner for the production of two proteins is a significant endorsement of our technology. The expression of those proteins turned out to be extremely difficult in other systems. With our CAP(R)Go technology, we are addressing an increasing need in the pharmaceutical, biotechnology and also veterinary industries for the efficient manufacturing of difficult-to-express therapeutic proteins with tailor-made glycosylation patterns for significantly improved physicochemical and pharmacological properties."
CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system.
CAP(R)Go enables the production of proteins previously out of reach representing a significant proportion of the human proteome that is notoriously difficult to express in conventional cell lines such as CHO. The CAP(R)Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with tailor made glycosylation patterns.
CEVEC Pharmaceuticals GmbH MC Services AG Dr. Nico Scheer Anne Hennecke Chief Business Officer Public Relations T.:+49 221 46020800 E.: email@example.com T.: +49 211 52925222 E.: firstname.lastname@example.org www.cevec.com
06.07.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de